title: Bortezomib and donor lymphocyte infusion in multiple myeloma relapsed after allo-SCT does not result in durable remissions.
authors.forename: I A
authors.initials: IA
authors.lastname: Hoevenaren
authors.forename: A
authors.initials: A
authors.lastname: Hoevenaren
authors.forename: L F D
authors.initials: LF
authors.lastname: van Vulpen
authors.forename: H
authors.initials: H
authors.lastname: Levenga
authors.forename: M C
authors.initials: MC
authors.lastname: Minnema
authors.forename: R
authors.initials: R
authors.lastname: Raymakers
mesh_terms: D000328:Adult; D000368:Aged; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D020350:Graft vs Tumor Effect; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017710:Lymphocyte Transfusion; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies; D014019:Tissue Donors; D014184:Transplantation, Homologous
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib